Holen Sie sich die Stockscreener-App
1.24
8.82%
-0.12
Schlusskurs vom Vortag:
$1.36
Offen:
$1.36
24-Stunden-Volumen:
979.57K
Relative Volume:
1.17
Marktkapitalisierung:
$135.79M
Einnahmen:
$78.09M
Nettoeinkommen (Verlust:
$-31.99M
KGV:
-3.416
EPS:
-0.363
Netto-Cashflow:
$-22.12M
1W Leistung:
-12.06%
1M Leistung:
-7.46%
6M Leistung:
-51.18%
1J Leistung:
-53.03%
1-Tages-Spanne:
$1.22
$1.36
1-Wochen-Bereich:
$1.22
$1.43
52-Wochen-Spanne:
$0.9583
$2.98
Codexis Inc Stock (CDXS) Company Profile
Firmenname
Codexis Inc
Sektor
Branche
Telefon
650-421-8100
Adresse
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
1.24 | 135.79M | 78.09M | -31.99M | -22.12M | -0.363 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-19 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-29 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-07 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-08-07 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2021-04-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-01 | Eingeleitet | Stifel | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-10 | Eingeleitet | The Benchmark Company | Buy |
| 2019-01-17 | Hochstufung | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | Eingeleitet | Stephens | Overweight |
| 2017-10-13 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-31 | Eingeleitet | Jefferies | Buy |
| 2017-01-26 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Codexis Inc Aktie (CDXS) Neueste Nachrichten
Codexis Inc (4QK.DU) interactive stock chart - Yahoo Finance Australia
Codexis CFO Georgia Erbez sells $8,619 of common stock - Investing.com
President and CEO Alison Moore sells $8,619 in Codexis stock - Investing.com
President and CEO Alison Moore sells $8,619 in Codexis stock By Investing.com - Investing.com South Africa
Form 4 Codexis Inc: Alison Moore (Director, President and CEO) For: 12 October - Investing.com Nigeria
An $8.62K share sale proposed by Codexis (CDXS) officer Georgia Erbez involves a vested stock grant. - Stock Titan
Officer Alison Moore proposes selling 6,335 Codexis (Nasdaq: CDXS) shares. - Stock Titan
Codexis (CDXS) Partners on Stereo-Defined siRNA Fragment Synthes - gurufocus.com
Codexis partners with siRNA innovator on enzyme synthesis By Investing.com - Investing.com Canada
Codexis partners with siRNA innovator on enzyme synthesis By Investing.com - Investing.com Nigeria
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA - Yahoo Finance Australia
Codexis Enters into an Agreement with Pioneering siRNA Drug - GlobeNewswire
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA - Yahoo Finance
Codexis (NasdaqGS:CDXS) Stock Forecast & Analyst Predictions - Simply Wall Street
Codexis at Cantor conference: enzymatic RNA manufacturing gains ground By Investing.com - Investing.com Canada
Codexis (CDXS) Q2 2026 Earnings: Loss Narrower Than Expected, Shares Decline 2.03%Revenue Per Share - vinanet.vn
Codexis (CDXS) Slides 3.61% to $1.60: Key Support Levels Under ScrutinyBollinger Expansion - vinanet.vn
Codexis (CDXS) Slides 3.61% to $1.60: Key Support Levels Under ScrutinyIV Rank - siam.in
Codexis to Participate in Cantor Global Healthcare Conference 2026 - GlobeNewswire
Codexis Management Will Participate in a Sept. 10 Fireside Chat - Stock Titan
Codexis to Participate in Cantor Global Healthcare Conference 2026 - Yahoo Finance
Codexis (CDXS) Financial Results: The Available Earnings Metric Delivers a Beat in the Latest Reading; Session Move - vinanet.vn
Codexis (CDXS) Financial Results: The Available Earnings Metric Delivers a Beat in the Latest Reading; Session Move - dars.gov.et
Codexis (CDXS) Q2 2026 Earnings Call Transcript - The Globe and Mail
CDXS Maintained by Piper Sandler -- Price Target Lowered to $8.0 - GuruFocus
CDXS Looks 39.1% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
CDXS Looks 39.1% Undervalued on GF Value™ - GuruFocus
Codexis (NASDAQ:CDXS) Cut to "Sell" at Wall Street Zen - MarketBeat
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Codexis (CDXS) investor Laurence Lytton discloses 5.2% beneficial stake in shares - Stock Titan
Codexis earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Codexis, Inc. Stock 12‑Month Price Target Cut to $6.5, Implies 339% Upside - TradingView
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocatalysis Growth and ECO Synthesis ... - finance.yahoo.com
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocataly - GuruFocus
Codexis, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
CDXS Looks 40.1% Undervalued on GF Value™ Amidst Challenging Fun - GuruFocus
Codexis narrows Q2 loss, raises $25M to fund GMP expansion - scanx.trade
Codexis Affirms FY26 Sales Guidance Range Amid Stable Outlook - scanx.trade
Transcript : Codexis, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Codexis (NASDAQ:CDXS) Issues Earnings Results - MarketBeat
Codexis Q2 Earnings Call Highlights - MarketBeat
Codexis Q2 Earnings Call Highlights - Yahoo Finance
CDXS: Q2 2026 saw revenue of $14.9M, margin gains, new financing, and major ECO Synthesis advances - tradingview.com
Earnings call transcript: Codexis beats Q2 2026 estimates as shares rise after hours - Investing.com
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
How Did Codexis Inc (CDXS) Perform in Q2? EPS at -0.14, Revenue Beats Estimates; GF Score: 49/100 - GuruFocus
Codexis, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CODEXIS ($CDXS) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Codexis: Q2 Earnings Snapshot - marketscreener.com
Codexis: Q2 Earnings Snapshot - 10TV
Finanzdaten der Codexis Inc-Aktie (CDXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Codexis Inc-Aktie (CDXS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MOORE ALISON | Officer |
Oct 12 '26 |
Proposed Sale |
1.36 |
6,335 |
8,619 |
0 |
| Erbez Georgia | Officer |
Oct 12 '26 |
Proposed Sale |
1.36 |
6,335 |
8,619 |
0 |
| MOORE ALISON | President and CEO |
Oct 12 '26 |
Sale |
1.36 |
6,335 |
8,619 |
244,171 |
| De Vre Raymond | Director |
Jun 11 '26 |
Sale |
2.37 |
2,605 |
6,174 |
84,811 |
| Lutz Stefan | Chief Scientific Officer |
Feb 24 '26 |
Sale |
1.13 |
5,862 |
6,641 |
130,421 |
| Lutz Stefan | Officer |
Feb 24 '26 |
Proposed Sale |
1.17 |
5,280 |
6,178 |
0 |
| Lutz Stefan | Officer |
Feb 06 '26 |
Proposed Sale |
1.27 |
2,460 |
3,124 |
0 |
| Norrett Kevin | Officer |
Feb 06 '26 |
Proposed Sale |
1.27 |
3,291 |
4,180 |
0 |
| MOORE ALISON | President and CEO |
Feb 06 '26 |
Sale |
1.31 |
3,826 |
5,001 |
250,506 |
| Erbez Georgia | See Remarks |
Feb 06 '26 |
Sale |
1.31 |
3,826 |
5,001 |
66,810 |
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):